Simultaneous splenectomy improving the outcomes of patients with hepatocellular carcinoma, cirrhosis and portal hypertension treated with hepatectomy
Portal Hypertension & Cirrhosis · 2022
DOI: 10.1002/poh2.29 ↗Kurz gefasst
Fachartikel in der Zeitschrift Portal Hypertension & Cirrhosis, 2022. Verfasst von Fuchen Liu und 11 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Aims
Patients with cirrhosis and clinically significant portal hypertension (CSPH) usually have concomitant secondary hypersplenism, and splenectomy (Spx) is an option for treating these patients in the Asia‐Pacific region. CSPH is the most important risk factor for postoperative liver dysfunction (PLD) in patients with hepatocellular carcinoma (HCC) and cirrhosis undergoing liver resection. However, the impact of simultaneous Spx and hepatectomy in patients with HCC and CSPH remains unclear. In this study, we aimed to determine the impact of simultaneous Spx on the posthepatectomy outcomes in these patients.
Methods
This study included 691 consecutive patients with hepatitis B virus‐related HCC, cirrhosis, and CSPH. These included 565 patients who underwent hepatectomy only (non‐Spx group) and 126 who underwent simultaneous hepatectomy and splenectomy (Spx group). We analyzed the effect of 25 preoperative and 5 intraoperative factors on postoperative outcomes using logistic regression. To overcome any possible selection bias, confounders were balanced by propensity score matching (PSM) and inverse probability of treatment weighting (IPTW) analyses, and subgroup analyses were performed within the PSM‐matched groups.
Results
Logistic regression analyses revealed that Spx was an independent protective factor for severe postoperative liver dysfunction (SPLD; odds ratio [OR] = 0.22, 95% confidence interval [CI]: 0.11–0.43, p < 0.001) and 90‐day SPLD‐related mortality (OR = 0.21, 95% CI: 0.06–0.55, p = 0.004), respectively. Spx was also independently associated with a higher overall survival rate (hazard ratio = 0.63, 95% CI = 0.47–0.85, p = 0.002) based on Cox regression analysis. PSM and IPTW models showed that the benefit of Spx was also consistent across the major and minor hepatectomy subgroups examined.
Conclusion
Simultaneous Spx improved the outcomes of patients with HCC, cirrhosis, and CSPH treated with hepatectomy, including patients who underwent major and minor hepatectomies.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Liu, F., Guo, X., Zhang, W., Zou, M., Huang, J., Dong, W., Zhang, J., Zhu, X., Pan, Z., Lau, W. Y., Zhou, W., & Liu, H. (2022). Simultaneous splenectomy improving the outcomes of patients with hepatocellular carcinoma, cirrhosis and portal hypertension treated with hepatectomy. Portal Hypertension & Cirrhosis. https://doi.org/10.1002/poh2.29
Vancouver
Liu F, Guo X, Zhang W, Zou M, Huang J, Dong W, et al. Simultaneous splenectomy improving the outcomes of patients with hepatocellular carcinoma, cirrhosis and portal hypertension treated with hepatectomy. Portal Hypertension & Cirrhosis. 2022. doi:10.1002/poh2.29
BibTeX
@article{Liu2022,
author = {Liu, Fuchen and Guo, Xinggang and Zhang, Wenli and Zou, Minghao and Huang, Jian and Dong, Wei and Zhang, Jinmin and Zhu, Xiuli and Pan, Zeya and Lau, Wan Yee and Zhou, Weiping and Liu, Hui},
title = {Simultaneous splenectomy improving the outcomes of patients with hepatocellular carcinoma, cirrhosis and portal hypertension treated with hepatectomy},
journal = {Portal Hypertension & Cirrhosis},
year = {2022},
doi = {10.1002/poh2.29}
}
EUVIMED